# US 2017/0285041 A1 · Method for determining risk of pre-eclampsia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0285041 A1
- Document ID: US20170285041A1
- Status: Published application
- Kind: A1
- Application number: 15/508,135
- Filed: 2015-09-01
- Published: 2017-10-05
- Earliest claimed: 2014-09-02
- Assignees: Wallac Oy
- Applicants: Wallac Oy
- Inventors: Tarja Ahola; Heikki Kouru; Mikko Sairanen
- Web page: https://patentgrep.com/patent/US20170285041A1

## CPC

- G01N 33/689: {related to pregnancy or the gonads}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 2333/70564: Selectins, e.g. CD62
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.

## Claims

### Claim 1

Method for determining the risk of pre-eclampsia in a pregnant individual with chronic hypertension, comprising: determining the levels of biochemical markers including Placental growth factor (PlGF) and sP-selectin in at least one blood sample from the individual; and determining the risk of pre-eclampsia using the determined levels of biochemical markers, wherein the levels of said biochemical markers are compared to control values of the same biochemical markers, and wherein a difference in the levels of said biochemical markers compared to control values of the same biochemical markers is indicative of early onset or late onset pre-eclampsia.

### Claim 2 (depends on 1)

The method according to claim 1, wherein decreased level of PlGF and increased level of sP-selectin in a sample obtained from a subject are indicative of increased risk of early or late onset pre-eclampsia.

### Claim 3 (depends on 1)

The method according to claim 1, wherein determining the risk further comprises using maternal history factors.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the sample is collected within first trimester.
